pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release

Wen-Yu Qian1,*, Dong-Mei Sun1,*, Rong-Rong Zhu1, Xi-Ling Du1, Hui Liu2, Shi-Long Wang1

1Shanghai Tenth People’s Hospital, School of Life Science and Technology, Tongji University, Shanghai, PR China; 2Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China

*Wen-Yu Qian and Dong-Mei Sun contributed equally to this work

Abstract: Strontium carbonate nanoparticles (SCNs), a novel biodegradable nanosystem for the pH-sensitive release of anticancer drugs, were developed via a facile mixed solvent method aimed at creating smart drug delivery in acidic conditions, particularly in tumor environments. Structural characterization of SCNs revealed that the engineered nanocarriers were uniform in size and presented a dumbbell-shaped morphology with a dense mass of a scale-like spine coating, which could serve as the storage structure for hydrophobic drugs. Chosen as a model anticancer agent, etoposide was effectively loaded into SCNs based on a simultaneous process that allowed for the formation of the nanocarriers and for drug storage to be accomplished in a single step. The etoposide-loaded SCNs (ESCNs) possess both a high loading capacity and efficient encapsulation. It was found that the cumulative release of etoposide from ESCNs is acid-dependent, and that the release rate is slow at a pH of 7.4; this rate increases significantly at low pH levels (5.8, 3.0). Meanwhile, it was also found that the blank SCNs were almost nontoxic to normal cells, and ESCN systems were evidently more potent in antitumor activity compared with free etoposide, as confirmed by a cytotoxicity test using an MTT assay and an apoptosis test with fluorescence-activated cell sorter (FACS) analysis. These findings suggest that SCNs hold tremendous promise in the areas of controlled drug delivery and targeted cancer therapy.

Keywords: strontium carbonate, nanoparticles, pH-sensitive drug delivery, etoposide, anticancer activity

Introduction

Nanocarriers for drug delivery have become key vehicles for the storage and delivery of drugs, especially anticancer drugs, because their small size enables them to leave the leaky tumor vasculature and accumulate at the tumor site through an enhanced permeability and retention (EPR) effect.1–3 Various nanocarriers including liposomes, polymers, micelles, dendrimers, gold, iron oxide, carbon-based materials, and silicon have been developed and explored as vehicles for the controlled release of anticancer drugs.4–13 However, most of the existing anticancer agents cannot distinguish between cancerous and healthy cells, leading to toxic actions and side effects. To further improve drug delivery efficiency and cancer specificity, tumor-targeting strategies have recently received significant attention.14,15

One of the most promising tumor targeting approaches is the investigation of pH-sensitive drug delivery systems, as the existing pH of tumor tissue is generally considered an ideal trigger for the selective release of anticancer drugs.16,17 Compared to normal tissue (pH 7.4), the average extracellular pH value in tumor tissues is 6.8, and the pH values of intracellular components such as endosomes and lysosomes are 4.5–6.5, which
is caused by hypoxia in poorly perfused regions due to the high metabolic rate required for tumor growth. The specificity of lower pH levels within the tumor region can be a strategy for acid-sensitive drug delivery at local microenvironments for not only improving the efficacy of chemotherapy, but also for reducing the level of cytotoxicity.

Recent studies have highlighted the development of some drug carriers with pH-sensitive, and therefore tumor-selective, drug delivery. Johnson et al., Lin and Kim, Li et al (micelles), Deng et al (chitosan-silica nanospheres), and Jin et al (polymers) all introduced new pathways for developing acid-response drug delivery systems. However, most of the pH-sensitive materials reported were organic-based, which may be less biocompatible, involve complicated manufacturing, and usually limit drug payloads (less than 15%). To circumvent these problems, the strategy of the present paper is to take advantage of the character and performance of inorganic materials in developing a targeted drug delivery system for anticancer drugs.

Inorganic nanocarriers as drug delivery vehicles have been investigated extensively in the past decade, and some of their benefits stem from their versatile properties such as being widely available, rich in functionality, offering favorable biocompatibility, and requiring mild preparation conditions; this field of research is further reinforced with continuous development of various new nanocarriers. Currently, many inorganic materials are being used for inorganic drug delivery (for instance, carbon materials, calcium phosphate, layered double hydroxide, gold, iron oxide, and silicon oxide), but for the most part these initiatives have been unsatisfactory. Critical properties of inorganic nanocarriers include nonbiodegradability, high leakage of drugs, and poor cellular internalization, which affect their efficiency in drug delivery. New strategies are therefore desired to address these limitations.

Here, we introduced strontium carbonate nanoparticles (SCNs) as nanocarriers for controlled drug delivery. Strontium (Sr), in human biology and pathology, has attracted less attention than the other two important divalent metals, calcium and magnesium. Although this is still true, there is an increasing awareness of the biological role of Sr after the development of the drug strontium ranelate, which has recently been shown to be an effective medication in the treatment of osteoporosis. Though a biomimetic system supported liquid membrane for obtaining SCNs was studied by Sun et al., few articles reported on the synthesis of SCNs. In this article, we initially came up with an in situ, single step, synchronous method for both the synthesis of SCNs and the loading of the hydrophobic drug into SCN carriers in mixed solvents.

Using the facile method, nontoxic SCNs of uniform size have been synthesized for biological applications. The samples were characterized, and their high efficiency as drug carriers was tested with a challenging anticancer drug, etoposide, which is generally applied, but has shown poor bioavailability in gastric cancer chemotherapy. It appeared as though the pH-sensitivity of SCNs yielded an improved performance in delivering the drug, suggesting that SCNs are innovative carriers for drug delivery.

**Materials and methods**

**Materials**

Etoposide (98%), dimethyl sulfoxide (DMSO), and MTT Formazan were purchased from Sigma Chemical Co (St Louis, MO). SrCl₂-6H₂O (AR), Na₂CO₃ (AR), citric acid (AR), HCl (36%–38%), and ethanol (AR) were purchased from Sinopharm Chemical Regent Co, Ltd (Shanghai, China). All the chemicals were used as received without further purification. Dulbecco's modified Eagle's medium (high glucose), RPMI-1640, fetal calf serum, penicillin G, streptomycin, and trypsinase were obtained from Gibco-BRL (Life Technologies Corporation, Grand Island, NY).

**Preparation of etoposide-loaded strontium carbonate nanoparticles**

All of the experiments were conducted at room temperature (about 15°C–25°C). In a typical procedure, the etoposide-loaded strontium carbonate nanoparticles (ESCNs) were prepared using 0.837 g of etoposide and 0.267 g SrCl₂-6H₂O, which were dissolved in a 180 mL mixed solvent of ethanol and deionized water (volume ratio = 8:1), marked as Solution A. A total of 0.106 g Na₂CO₃, was dissolved in a 180 mL mixed solvent of ethanol and deionized water (volume ratio = 1:1), marked as Solution B. After 0.026 g citric acid was added into Solution A, Solution B was added drop-wise to the vigorously stirred Solution A and reacted for 24 hours. The product was centrifuged, washed thrice with deionized water, and dried at 60°C. The blank carrier strontium carbonate nanoparticles (SCNs) were prepared without the addition of etoposide, and other experimental parameters used were similar to that of the ESCNs sample.

**Characterization**

The spatial and morphological studies were carried out with field emission scanning electron microscopy (S4800; Hitachi Ltd, Tokyo, Japan) at an accelerating voltage of 1–5 kV. The crystallographic structure of the solid samples was determined with X-ray diffraction (XRD,
Bruker D8; Bruker AXS, Inc, Madison, WI) with Cu Kα radiation (λ = 0.154056 nm, 40 kV, 40 mA, step of 0.0330°). The average particle size (z-average size) and size distribution were measured using photon correlation spectroscopy (LS230, Beckman Coulter Inc, Brea, CA) at 25°C under a fixed angle of 90° in disposable polystyrene cuvettes. The measurements were conducted using a He-Ne laser of 633 nm. Fourier transform infrared spectra were obtained on a Bruker Vector 22 (Bruker AXS, Inc) spectrophotometer in the range of 4000–400 cm−1 using the standard KBr disk method (sample/KBr = 1/100). Ultraviolet-visible (UV-vis) spectra were measured on a Cary 50UV-visible absorbance spectrophotometer (Varian, Victoria, Australia).

Sedimentation study in phosphate-buffered solution (PBS)
A total of 10 mg of etoposide was placed in a microcentrifugal tube of 1.5 mL and resuspended with 1 mL of PBS. The tube then stood for over 8 hours after vortexing for 1 minute. Photographs of the sample were taken at 10 minutes, 3 hours, and 8 hours, respectively. Other samples were studied in the same way. Based on the drug encapsulation efficiency, the same quantity of etoposide was applied to all formulations for the sedimentation study.

Evaluation of the buffer effect
The pH, which changes in each suspension after the addition of 0.1 M HCl aqueous solution, was recorded to measure the buffer effect of prepared samples. HCl aqueous solution was subsequently added to the suspension (10 mL) containing the prepared sample (100 mg), and was continuously stirred at 37°C, until the pH dropped to an approximate value of 2.5.

Determination of loading amount and in vitro release test
The amount of entrapped etoposide was determined by UV-vis spectroscopy. An ESCN sample of a standard weight was placed in a 10 mL flask, then 1 mL of 3 M HCl solution was added into it, and the flask was filled with 0.02 M of PBS (pH 7.4) until the total volume reached 10 mL. After the ESCNs sample was totally dissolved, the concentration of etoposide was determined with a UV-vis spectrophotometer. The selected wavelength used for the measurement of the etoposide was 285 nm. The concentration of the etoposide was calculated according to an already obtained calibrating curve (Abs = 0.00746c + 0.000967, r = 0.99985). The drug-loading capacity and encapsulation efficiency are calculated by:

\[
\text{Drug Loading capacity} = \frac{\text{Weight of etoposide in ESCNs}}{\text{Weight of ESCNs}} \times 100\%
\]

\[
\text{Drug encapsulation efficiency} = \frac{\text{Weight of etoposide in ESCNs}}{\text{Weight of etoposide fed initially}} \times 100\%
\]

The etoposide release test was performed as follows: 100 mg of ESCNs were resuspended in 5 mL of PBS at pH 7.4, pH 5.8, and pH 3.0. A dialysis bag was pretreated with ethylenediaminetetraacetic acid, loaded with the sample, placed in a flask of 500 mL with 200 mL of PBS at same pH value, and swayed in a bath-reciprocal shaker at 100 rpm at 37°C over 72 hours. A total of 1 mL of the fluid containing the released etoposide was extracted at desired time intervals, and another 1 mL of fresh PBS was added to the medium. The accumulated amount of released etoposide was determined by UV absorption at 285 nm.

Cytotoxicity assay
Human embryonic kidney (HEK) 293T cells with a density of 1 × 10⁴ cells/well were seeded on a 96-well polystyrene plate, and each well contained 100 µL of Dulbecco’s modified Eagle’s medium (high glucose) supplemented with 10% fetal bovine serum and a 1% penicillin-streptomycin solution. After incubation at 37°C in a 5% CO₂ humid environment for 24 hours, triplicate wells were treated with SCNs, free etoposide, and ESCNs in different concentrations of 5, 10, 20, and 40 µg/mL. These HEK293T cells were incubated as described above for 24 and 48 hours, respectively. Cells did not treat with any agents served as a blank control. The number of living cells was determined by MTT assay with 3-(4,5-dimethyl-thiazole-2-yl)-2,5-phenyltetrazolium bromide. After cells were incubated with 20 µL of MTT (5 mg/mL) for 4 hours at 37°C under a light-blocking condition, the medium was removed and 150 µL of DMSO was added into each well. Absorbance was measured as at 490 nm using the ELx800 reader (BioTek Instruments, Inc, Winooski, VT), and cell viability was calculated by:

\[
\text{Cell viability} = \frac{\text{OD}_{490} \text{ (test)} - \text{OD}_{490} \text{ (blank)}}{\text{OD}_{490} \text{ (control)} - \text{OD}_{490} \text{ (blank)}} \times 100\%
\]

Inhibition against SGC-7901 cells
Human gastric carcinoma (SGC-7901) cells with a density of 8 × 10⁴ cells/well were seeded on a 96-well polystyrene plate; each well contained 100 µL of Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin solution. After incubation at
37°C in 5% CO₂ humidity for 24 hours, triplicate wells were treated with SCNs, free etoposide, and ESCNs in different concentrations of 5, 10, 20, and 40 µg/mL. Based on the drug encapsulation efficiency, the same quantity of etoposide was applied to all formulations for the growth inhibition study. These HEK293T cells were incubated as described above for 24 and 48 hours, respectively. A control experiment was performed without treated under the same conditions. A total of 20 µL (5 mg/mL) of MTT dye solution was added to each well before the cells were incubated for 4 hours at 37°C under a light-blocking condition. The medium was then removed and 150 µL of DMSO was added into each well. Absorbance was measured at 490 nm using an ELx800 reader (BioTek Instruments, Inc, Winooski, VT), and inhibition against SGC-7901 cells was calculated by:

\[
\text{Inhibition (\%) = \left(1 - \frac{OD_{490\text{ (test)}} - OD_{490\text{ (blank)}}}{OD_{490\text{ (control)}} - OD_{490\text{ (blank)}}}\right) \times 100%}
\]

**Fluorescence activated cell sorter (FACS) analysis**

The number of apoptotic cells was determined with the Annexin V-PI Detection KIT (keyGEN, Nanjing, China). SGC-7901 cells with a density of 1 × 10⁶ cells/well were seeded on a 24-well polystyrene plate suspended in RPMI-1640 with 10% pasteurized fetal calf serum and incubated for 24 hours at 37°C. The free etoposide, ESCNs, and culture medium were only added to each group at a concentration of 10 µg/mL. Based on the drug encapsulation efficiency, the same quantity of etoposide was applied to all formulations for the apoptosis analysis. The incubation continued for 24 hours at 37°C. The cells were then harvested and washed with PBS, and propidium iodide (PI) and annexin V were added directly to the cells suspended in the binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl₂, pH 7.4). The cells were incubated in the dark for 15 minutes at 37°C and were submitted to FACS analysis on a Becton-Dickinson (Becton, Dickinson and Company, Mountain View, CA) spectrophotometer.

**Results and discussion**

As shown in Figure 1, the synthetic scheme of ESCNs (SEM images shown in Figure 2) for drug delivery has been proposed. A mixed solvent method was employed to enable the simultaneous achievement of facilitated preparation for nanoscale particles,³⁸ and a high concentration of a hydrophobic drug (etoposide) could be made since ethanol was involved. Citric acid was used here as a crystal modifier to control the selectivity of polymorph and crystal morphology during the process of mineralization. After ionization, citric acid produces H⁺ ions, which meet with HCO₃⁻ ions, and then generate CO₂ and H₂O. The CO₂ bubble acts not only as the reactive material (hydrated and transformed into CO₃²⁻ ions and H⁺ ions), but also as the template of engineered nanoparticles, for the newly formed primary particles can attach to CO₂ bubbles and have their crystal forms modified (reaction formulas listed below). As a result, dumbbell-shaped SCNs have been prepared (SEM images shown in Figure 2). These nanoparticles present a dense mass of scale-like spine coating, which can easily entrap the drug in large amounts in a rapid stirring synthetic system.

---

**Figure 1** A representative illustration of the synthesis system and SCNs before or after drug loading.

**Abbreviations:** SCNs, strontium carbonate nanoparticles; ESCNs, etoposide-loaded strontium carbonate nanoparticles.

**Figure 2** SEM images of engineered SCNs with different enlarging ratios.

**Abbreviations:** SEM, scanning electron microscope; SCNs, strontium carbonate nanoparticles.
during and after the crystallization of SCNPs. Accordingly, the synthesis of ESCNs was based on a simultaneous process of both nanocarrier formation and drug storage, which was accomplished in a single step.

\[
2\text{RCOOH}(\text{aq}) + \text{CO}_3^{2-} = 2\text{RCOO}^- + \text{H}_2\text{O}(\text{aq}) + \text{CO}_2(\text{g}) \\
\text{CO}_2(\text{g}) \rightleftharpoons \text{CO}_2(\text{aq}) \\
\text{CO}_2(\text{aq}) + \text{H}_2\text{O}(\text{aq}) \rightleftharpoons \text{HCO}_3^- + \text{H}^+ \\
\text{HCO}_3^- \rightleftharpoons \text{H}^+ + \text{CO}_3^{2-} \\
\text{Sr}^{2+} + \text{CO}_3^{2-} = \text{SrCO}_3(s)
\]

The morphology of the dumbbell-shaped nanoparticles of uniform size with good dispersal properties synthesized via the mixed solvent method is shown in Figure 2. It can be observed that the engineered SCNPs present a dense mass of a scale-like spine coating, which can serve as the storage structure for hydrophobic drugs and prevent them from leaking out of the nanovehicles. The subunit’s distribution size of engineered SCNPs is narrow, with a nominal mean hydrodynamic diameter of 86.8 nm (image shown in Figure 4). All of these typical features of SCNPs make them promising for biological applications.

The curve in Figure 3 shows the XRD pattern of prepared SCNPs crystals, as well as a standard XRD pattern of SrCO$_3$. All diffraction peaks of the prepared products can be readily indexed to a pure orthorhombic phase of strontianite with lattice constants \(a = 5.107 \text{ Å}, b = 8.414 \text{ Å}, \) and \(c = 6.209 \text{ Å}\) (data from JCPDS file number 05-0418). In addition, diffraction peaks of SCNPs broadened due to a nanosize effect, and no additional peaks of other phases were found, indicating that the SCNPs have been well crystallized and are of high purity.

UV-vis spectra of SCNPs, etoposide, and ESCNs were obtained. The absorption curves of all samples incubated in 1 M HCl solution for 24 hours are shown in Figure 5. It was found that the curve of etoposide shows the characteristic absorption peak at approximately 285 nm, similar to what has been reported in the literature. From the spectra of ESCNs, it can be observed that an obvious absorption emerged at 285 nm, which revealed that the carriers of ESCNs degraded in the acidic condition after 24 hours, releasing etoposide out in the solution. This suggests that etoposide was likely packed in the dense scale-like spine structure of the SCNPs. In comparison, no absorption peaks were shown in the spectra of SCNPs at 285 nm.

As shown in Figure 6, the Fourier transform infrared spectra of the sample etoposide (a), ESCNs (b), and SCNPs (c) were obtained. The bands noted around 3400 cm$^{-1}$ were derived from the band vibration of O–H. The spectra of SCNPs (c) displayed two strong absorption bands at 856 cm$^{-1}$ and 1465 cm$^{-1}$, which are characteristic bands of SrCO$_3$, which are in agreement with the results shown in the XRD patterns. The spectra of etoposide (a) show the following selected bands: 2923 cm$^{-1}$ (C–H stretch), 1770 cm$^{-1}$ (C=O stretch of ester bond), 1613 cm$^{-1}$ (C=O stretch of carboxyl methyl), and 1056 cm$^{-1}$ (C–O–C stretch), as well as the bands at 1487 cm$^{-1}$ and 1405 cm$^{-1}$, which correspond to the C=C stretching in the backbone of the aromatic phenyl ring. Compared with that of SCNPs and etoposide, the spectra of ESCNs (b) present the characteristic bands of SrCO$_3$, which are consistent with the results shown in Figure 5.

Figure 7 presents the photographs of SCNPs, etoposide, and ESCNs in double distilled water (ddH$_2$O), which were recorded at 10 minutes, 3 hours, and 8 hours after standing. As shown in Figure 7, both SCNPs and ESCNs dispersed stably in ddH$_2$O, and hardly any sedimentation of the particles was observed after standing for 8 hours. In contrast with nanoagents, the free etoposide added in ddH$_2$O began to be precipitated and aggregated in the initial 10 minutes, while most of the sample remained sedimentary at the bottom of the tube after standing for 8 hours, even though there was a trace.

**Figure 3** XRD pattern of engineered SCNPs and standard pattern of SrCO$_3$ (JCPDS 05-0418).

**Abbreviations:** XRD, X-ray diffraction; SCNPs, strontium carbonate nanoparticles.
amount of dissolution. Therefore, the embedding of etoposide into SCNs is an effective means of improving the dispersion and stability of the drug in an aqueous suspension.

In our case, the ESCNs held both a high drug-loading capacity (34.4% ± 0.3%) and increased encapsulation efficiency (71.6% ± 1.9%). Since the therapeutic effectiveness of the drug is closely related to the release performance of the drug delivery system in the body, the in vitro release of the ESCNs was modeled in the different pH environments for blood and normal tissue (pH 7.4), tumor microenvironment (pH 5.8), in gastric juice (pH 3.0), and in three different buffered solutions for 72 hours at 37°C. The results are shown in Figure 8.

With the incremental release time, the amount of etoposide in the solution increased. In all chosen solutions, the drug release was fast during the first 24 hours. This may be attributed to the drug molecules that were packed in the structure of the dense scale-like spine coating of the SCNs. After that point, the release rate slowed down; in addition, the amount of etoposide released from the ESCNs occurred in the following order: pH 3.0 > pH 5.8 > pH 7.4. The faster release of etoposide in acidic conditions (especially in the strong acidic condition) may be due to the acid-degradable nature of SCNs. At a pH of 7.4 the release amount was quite low, and only approximately 23% of the drug was released in 72 hours, with no ‘burst effect’, which suggests that the delivery process might be primarily governed by diffusion from the outer layer rather than from the degradation of ESCNs. At a pH of 5.8, the release curve leveled off after 39 hours, and the release amount was 66% in 72 hours. It is noted that when the pH decreased to 3.0, a faster release behavior was observed, and the release amount reached 83%
in 72 hours, which was 3.6 times of that at a pH level of 7.4. These results can demonstrate that the engineered ESCNs are a pH-sensitive controlled drug-delivery system, which may be of particular feasibility in achieving gastric tumor-targeted therapy.

Suppose that oral administration is chosen; the ESCNs can be resistant to gastric acids and ensure a stable delivery of etoposide during the brief stay in stomach (typically, 3–4 hours). When the nanohybrids accumulate at the tumor site through the EPR effect upon circulation in the blood vessels, a fast and stable etoposide release can be triggered in response to extracellular or intracellular chemical stimulation of tumor cells, where the pH value is lower than in the normal tissue. As a result, a gastric cancer treatment is expected to be carried out in multiple ways through a targeted and safe method of delivery, with minimal side effects.

The pH-buffering properties of SCNs, etoposide, and ESCNs were tested by a titration method. The correlation between pH value and added volume of a 0.1 M HCl solution is shown in Figure 9. The pH curves of both SCNs and ESCNs revealed that there was a profound buffer effect as the pH value was maintained at around 6.0 with the addition of a few mL of a 0.1 M HCl solution, while etoposide presented with a poor buffering property; this could be explained by the fact that strontium carbonate is acid-degradable. A three-phase release process can be observed. At the first stage, with the addition of 0.1 M HCl, the scaly exfoliation of SCNs was made by HCl to induce the destruction of the integrity of the coating layer, which resulted in a sharp decrement of the solution pH from about 8 to 6. Along with the degradation of ESCNs as the strontium carbonate in nanoparticles reacted with the HCl, the pH of the medium solution was maintained at about 6 (at the intermediate stage), which was dependent on the neutralization value of SCNs. At the last stage, the pH of the medium solution was cut down and was reduced to 2, as the strontium carbonate in the nanoparticles

---

**Figure 7** Sedimentation photographs of SCNs, free etoposide, and ESCNs in double distilled water after standing for 10 minutes, 3 hours, and 8 hours.

**Abbreviations:** SCNs, strontium carbonate nanoparticles; ESCNs, etoposide-loaded strontium carbonate nanoparticles.

**Figure 8** Release profiles of etoposide from ESCNs under simulated physiological conditions. (A) Release profiles of etoposide from ESCNs under simulated physiological conditions (pH 3.0, pH 5.8, and pH 7.4 at 37°C); (B) release profiles in the initial 4 hours.

**Note:** All experiments were carried out in triplicate.

**Abbreviation:** ESCNs, etoposide-loaded strontium carbonate nanoparticles.
was consumed by HCl. Compared with SCNs, the ESCNs can dissolve fast since their structure was mixed with the drug, etoposide. In effect, ESCNs are more easily dissolved, which further reduces the buffering effect. Nevertheless, ESCNs may significantly buffer the drug microclimate in gastric fluids compared with free etoposide.

Figure 10A and B show the viability of HEK293T cells treated with SCNs, free etoposide, and ESCNs at various concentrations for 24 and 48 hours, respectively. The average residual HEK293T cells remained over 90% after being incubated with SCNs for 48 hours, even at the highest tested dose, indicating that SCNs were highly biocompatible with HEK293T cells. Compared with free etoposide, ESCNs presented no obvious cytotoxicity against normal cells. The data reveals the good biocompatibility and stable drug-loading effect of the nanocarriers.

Figure 10C and D show the effect of etoposide formulation on the inhibition against SGC-7901 cell growth. Time-dependent inhibition of SGC-7901 cells treated with the samples was indicated. With increased incremental treatment durations, the viability of SGC-7901 cells was reduced. The order of the inhibitory efficacy on SGC-7901 cells was ESCNs > etoposide > SCNs. The rationale behind this order can be explicated below. Good dispersion of ESCNs in an aqueous solution facilitates greater cellular uptake than that of free etoposide. Furthermore, with a sustained release of drug triggered in the acidic microenvironment of SGC-7901 cells, ESCNs can make the most efficient delivery of etoposide into the tumor cells. After treatment with ESCNs over 48 hours, the average residual SGC-7901 cells were about 17% among the control group. This value was about one-third of the percentage of the number of SGC-7901 cells treated with the free etoposide solution. Synergistic therapeutic effects occurred when etoposide combined with SCNs. In parallel, the empty nanoparticles demonstrated no significant inhibitory effect.

Results of the apoptosis assay after staining cells with annexin V-FITC, using PI labeling, and using FACS for determining the percentages of early and late apoptotic cells are illustrated in Figure 11. Early apoptosis was characterized by plasma membrane reorganization and was detected by positive staining for annexin V-FITC, while later stage apoptosis indicating DNA damage showed positive staining for both annexin V and PI. SGC-7901 cells were treated with 10 µg/mL of ESCNs as well as with free etoposide for 24 hours prior to FACS analysis; meanwhile, cells without any additives were set as controls. As shown in Figure 11A, SGC-7901 cells without any additives showed 0.17% early apoptosis and 0.20% later apoptosis. The treatment with etoposide led to early apoptosis in 8.95% of cells, and to later apoptosis in 2.06% of cells (Figure 11B). Remarkably, the percentage of cells that reached early apoptosis increased to 29.38%, and the percentage of cells that reached later apoptosis increased to 5.20% (Figure 11C) when the cells were treated with ESCNs.

Etoposide can cause apoptosis cascade in gastric cancer cells by coupling DNA damage to p53 phosphorylation through the action of DNA-dependent protein kinase. As the activation of p53 increases, Bax synthesis and the translocation of Bax to the mitochondria induces the mitochondrial permeability transition, the event that releases cytochrome c and culminates in the death of the cells. The percentage of both early apoptosis and later apoptosis in ESCNs is significantly increased compared with free etoposide and untreated controls, which confirms that ESCNs were able to induce the apoptosis processes among gastric cancer cells and readily caused the cells to die. Therefore, ESCNs may be more readily taken up by SGC-7901 cells and could protect etoposide from rapid decomposition. The results also prove that etoposide entrapped in SCNs can enhance the anticancer efficiency of the drug and serve as excellent vehicles for anticancer drug release.

The tumor targeting process of pH-sensitive ESCNs in the body may be conjectured as follows (scheme shown in Figure 12). As tumor vessels are often dilated and fenestrated with an average pore size of less than 1 µm compared with normal tissue due to rapid formation of...
vessels that must serve the fast-growing tumor, the nanoscale size enables ESCNs to leave the tumor vasculature through the leaky endothelial tissue and then accumulate in solid tumors by the EPR effect, while normal tissues contain capillaries with tight junctions that are less permeable to nanosized particles. After that, rapid and sustained release of etoposide from ESCNs is triggered in response to low pH in relatively acidic extracellular fluids in the tumor, or after endocytosis in the endosomes or lysosomes in tumor cells, together with the degradation of the nanocarriers. It should be noted that in this process of tumor targeting, both penetration through blood vessels and cellular internalization of drug-containing particles are likely to play a key role in determining their targeted and biological activity. As reported, these processes result in changes in the size of the particles, rather than binding in the form of “passive targeting.” In most studies, tumors exhibited a vascular pore cutoff size ranging from 400 nm to 800 nm, cells.
and permeability to a particle is independent of pore cutoff size as long as the diameter of the particle is much less than the pore diameter. Studies have shown that particles with diameters less than 200 nm are small enough to avoid nonselective uptake by macrophages of the reticuloendothelial system, and are more effective when they accumulate at the tumor site via the EPR effect upon circulation in the blood vessels. Also, conclusions have been drawn that nanoparticles with a diameter of less than 200 nm may determine the almost exclusive internalization along the pathway of clathrin-coated pits rather than via caveolae. These results suggest that the engineered pH-sensitive ESCNs with a size of 86.8 nm might have great potential in cancer therapy, for their capability of permeation and retention within the tumor region can be enhanced due to their favorable size. Further in vivo delivery of ESCNs in an animal model will be performed to verify this conjecture.

**Conclusion**

SCNs were initially designed and engineered as nanocarriers via a biologically and environmentally favorable one-step mixed solvent method with citric acid as a crystal modifier, aimed at producing high efficiency in tumor-selective drug delivery. The dumbbell-shaped nanoparticles of a uniform size (86.8 nm) present a good dispersivity in aqueous solution. Etoposide as a model drug was successfully entrapped into ESCNs based on a simultaneous process that both the formation of the nanocarriers and the storage of the drug were accomplished in a single step, and the ESCNs possessed both a high loading capacity (34.4%) and encapsulation efficiency (71.6%). The cumulative release of etoposide from the nanocarriers showed a low leakage at pH 7.4 with only 23% of the drug released after 72 hours, while this rate was significantly enhanced to 66% at a pH of 5.8, and 83% at a pH of 3.0. These results demonstrated that the drug release of ESCNs was likely pH-sensitive. The cytotoxicity test and apoptosis test showed that the blank carrier SCNs were almost nontoxic, and the ESCNs were evidently more potent in antitumor activity when compared with free etoposide. These results indicated that the SCNs hold great promise for the development of efficient and selective tumor therapy. These promising results encourage us to perform further in vivo delivery of drugs in an animal model in the future.

**Acknowledgments**

This work was financially supported by the 973 project of the Ministry of Science and Technology (Grant No 2010CB912604, 2010CB933901), the National Natural Science Foundation of China (Grant No 31140038), International Science and Technology Cooperation Program of China, (Grant No 0102011DFA32980), Science and Technology Commission of Shanghai Municipality (Grant No 11411951500), and the Fundamental Research Funds for the Central Universities.
Disclosure

The authors report no conflict of interest in this work.

References


